Back to Results
First PageMeta Content
Pharmacology / Clinical research / Design of experiments / Clinical trial / Drug discovery / Pharmaceutical industry / Irritable bowel syndrome / Food and Drug Administration / Linaclotide / Health / Medicine / Pharmaceutical sciences


Microsoft Word - Tioga SPA PR FINAL
Add to Reading List

Document Date: 2011-08-15 11:58:27

Open Document

File Size: 16,51 KB

Share Result on Facebook

City

SAN DIEGO / /

Company

Tioga Pharmaceuticals Inc. / Special Protocol Assessments An SPA / Tioga Pharmaceuticals Tioga Pharmaceuticals Inc. / Tioga Pharmaceuticals / /

Country

United States / /

Event

FDA Phase / /

Facility

About Special Protocol Assessments An SPA / /

IndustryTerm

efficacy protocols / pharmaceutical / /

MedicalCondition

diarrhea-predominant irritable bowel syndrome / pain / gastrointestinal diseases / bloating / /

Organization

FDA / U.S. Food and Drug Administration / /

Person

Allen Mangel / /

Position

Chief Medical Officer / /

Product

only one drug / Asimadoline / /

ProvinceOrState

California / /

Technology

3 efficacy protocols / /

URL

www.tiogapharma.com / /

SocialTag